Global Stem Cell Therapy Market

Stem Cell Therapy Comprehensive Study by Therapy Type (Autologous Stem Cell Therapy, Allogeneic Stem Cell Therapy), Cell Source (Adult Stem Cells, Embryonic Stem Cells, Induced Pluripotent Stem Cells (iPSCs)), Application (Musculoskeletal Disorders, Cardiovascular Diseases, Neurological Disorders, Oncology, Wounds and Injuries, Others), End User (Hospitals & Clinics, Academic & Research Institutes, Biotechnology & Pharmaceutical Companies) Players and Region - Global Market Outlook to 2032

Stem Cell Therapy Market by XX Submarkets | Forecast Years 2025-2032 | CAGR: 13.8%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Stem Cell Therapy Market Overview:
Stem cell therapy is a cutting-edge area of regenerative medicine that deals with the application of stem cells to mend, replace, or regenerate lost or damaged tissues and organs in the human body. These therapies take advantage of the special property of stem cells to develop into specialized cell types, holding great promise for the treatment of a variety of medical disorders such as neurodegenerative diseases, cardiovascular disease, orthopedic trauma, autoimmune diseases, and various cancers. Stem cell therapies are generally classified into autologous (with the patient's own cells) and allogeneic (using donor cells) therapies. The market for stem cell therapy is growing at a very fast rate globally because of mounting clinical trials, rising investment in regenerative medicine, and technological advancements in stem cell banking, gene editing technologies, and biomanufacturing. Governments and companies are heavily investing in research and development for this sector, as patient need for long-term, minimally invasive treatments keeps expanding. Top drivers are increasing incidence of chronic diseases, an expanding aging population, and greater awareness for personalized medicine. Yet, ethical issues, regulatory barriers, and high cost of treatment remain obstacles to overcome. As per latest study released by AMA Research, the Global Stem Cell Therapy market is expected to see growth rate of 13.8%

AttributesDetails
Study Period2020-2032
Base Year2024
Forecast Period2022-2032
Historical Period2020-2024
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Growing popularity of stem cell banking for future therapeutic use. and Integration of AI and machine learning in stem cell research for predictive modeling and treatment optimization.

Market Growth Drivers:
Expanding applications of stem cell therapy and Rising prevalence of chronic diseases and degenerative conditions

Challenges:
Long-term safety and efficacy validation of stem cell therapies still under evaluation. and Limited reimbursement frameworks for stem cell-based treatments in many healthcare systems.

Restraints:
Ethical concerns, particularly around embryonic stem cell usage. and High cost of therapy development and treatment

Opportunities:
Development of combination therapies involving stem cells and biologics or drugs. and Rising demand for anti-aging and cosmetic treatments using stem cell technology.

Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Mesoblast Ltd., Athersys, Inc., Osiris Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vericel Corporation, Pluristem Therapeutics Inc., BioTime, Inc. (Lineage Cell Therapeutics), Cynata Therapeutics Limited, Thermo Fisher Scientific Inc., STEMCELL Technologies Inc., FUJIFILM Cellular Dynamics, Inc., BrainStorm Cell Therapeutics Inc., Gamida Cell Ltd., BlueRock Therapeutics and ReNeuron Group plc. Considering Market by Therapy Type, the sub-segment i.e. Autologous Stem Cell Therapy will boost the Stem Cell Therapy market. Considering Market by Cell Source, the sub-segment i.e. Adult Stem Cells will boost the Stem Cell Therapy market. Considering Market by Application, the sub-segment i.e. Musculoskeletal Disorders will boost the Stem Cell Therapy market. Considering Market by End User, the sub-segment i.e. Hospitals & Clinics will boost the Stem Cell Therapy market.

Latest Market Insights:


In March 2025, Neurotech Pharmaceuticals launched Encelto (revakinagene taroretcel), an allogeneic encapsulated cell-based gene therapy approved by the FDA for the treatment of macular telangiectasia type 2. and In January 2025, Vertex Pharmaceuticals and CRISPR Therapeutics received NHS approval in England for Casgevy (exagamglogene autotemcel), a gene-editing therapy for sickle cell disease, utilizing CRISPR technology to edit patients' stem cells.

What Can be Explored with the Stem Cell Therapy Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Stem Cell Therapy Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Stem Cell Therapy
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Stem Cell Therapy market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Stem Cell Therapy market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Hospitals and Specialty Clinics, Biotechnology and Pharmaceutical Companies, Academic and Research Institutes, Stem Cell Banks, Regulatory and Government Healthcare Agencies, Contract Research Organizations (CROs), Healthcare Providers and Practitioners, Medical Device and Equipment Manufacturers, Investors and Venture Capital Firms and Patients and Patient Advocacy Groups.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Therapy Type
  • Autologous Stem Cell Therapy
  • Allogeneic Stem Cell Therapy

By Cell Source
  • Adult Stem Cells
  • Embryonic Stem Cells
  • Induced Pluripotent Stem Cells (iPSCs)

By Application
  • Musculoskeletal Disorders
  • Cardiovascular Diseases
  • Neurological Disorders
  • Oncology
  • Wounds and Injuries
  • Others

By End User
  • Hospitals & Clinics
  • Academic & Research Institutes
  • Biotechnology & Pharmaceutical Companies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Expanding applications of stem cell therapy
      • 3.2.2. Rising prevalence of chronic diseases and degenerative conditions
    • 3.3. Market Challenges
      • 3.3.1. Long-term safety and efficacy validation of stem cell therapies still under evaluation.
      • 3.3.2. Limited reimbursement frameworks for stem cell-based treatments in many healthcare systems.
    • 3.4. Market Trends
      • 3.4.1. Growing popularity of stem cell banking for future therapeutic use.
      • 3.4.2. Integration of AI and machine learning in stem cell research for predictive modeling and treatment optimization.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Stem Cell Therapy, by Therapy Type, Cell Source, Application, End User and Region (value) (2019-2024)
    • 5.1. Introduction
    • 5.2. Global Stem Cell Therapy (Value)
      • 5.2.1. Global Stem Cell Therapy by: Application (Value)
        • 5.2.1.1. Musculoskeletal Disorders
        • 5.2.1.2. Cardiovascular Diseases
        • 5.2.1.3. Neurological Disorders
        • 5.2.1.4. Oncology
        • 5.2.1.5. Wounds and Injuries
        • 5.2.1.6. Others
      • 5.2.2. Global Stem Cell Therapy by: Therapy Type (Value)
        • 5.2.2.1. Autologous Stem Cell Therapy
        • 5.2.2.2. Allogeneic Stem Cell Therapy
      • 5.2.3. Global Stem Cell Therapy by: Cell Source (Value)
        • 5.2.3.1. Adult Stem Cells
        • 5.2.3.2. Embryonic Stem Cells
        • 5.2.3.3. Induced Pluripotent Stem Cells (iPSCs)
      • 5.2.4. Global Stem Cell Therapy by: Application (Value)
        • 5.2.4.1. Musculoskeletal Disorders
        • 5.2.4.2. Cardiovascular Diseases
        • 5.2.4.3. Neurological Disorders
        • 5.2.4.4. Oncology
        • 5.2.4.5. Wounds and Injuries
        • 5.2.4.6. Others
      • 5.2.5. Global Stem Cell Therapy by: End User (Value)
        • 5.2.5.1. Hospitals & Clinics
        • 5.2.5.2. Academic & Research Institutes
        • 5.2.5.3. Biotechnology & Pharmaceutical Companies
      • 5.2.6. Global Stem Cell Therapy Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
  • 6. Stem Cell Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2024)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Mesoblast Ltd.
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Athersys, Inc.
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Osiris Therapeutics, Inc.
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda Pharmaceutical Company Limited
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Vericel Corporation
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pluristem Therapeutics Inc.
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. BioTime, Inc. (Lineage Cell Therapeutics)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Cynata Therapeutics Limited
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Thermo Fisher Scientific Inc.
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. STEMCELL Technologies Inc.
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. FUJIFILM Cellular Dynamics, Inc.
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. BrainStorm Cell Therapeutics Inc.
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Gamida Cell Ltd.
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. BlueRock Therapeutics
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. ReNeuron Group plc
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
  • 7. Global Stem Cell Therapy Sale, by Therapy Type, Cell Source, Application, End User and Region (value) (2027-2032)
    • 7.1. Introduction
    • 7.2. Global Stem Cell Therapy (Value)
      • 7.2.1. Global Stem Cell Therapy by: Application (Value)
        • 7.2.1.1. Musculoskeletal Disorders
        • 7.2.1.2. Cardiovascular Diseases
        • 7.2.1.3. Neurological Disorders
        • 7.2.1.4. Oncology
        • 7.2.1.5. Wounds and Injuries
        • 7.2.1.6. Others
      • 7.2.2. Global Stem Cell Therapy by: Therapy Type (Value)
        • 7.2.2.1. Autologous Stem Cell Therapy
        • 7.2.2.2. Allogeneic Stem Cell Therapy
      • 7.2.3. Global Stem Cell Therapy by: Cell Source (Value)
        • 7.2.3.1. Adult Stem Cells
        • 7.2.3.2. Embryonic Stem Cells
        • 7.2.3.3. Induced Pluripotent Stem Cells (iPSCs)
      • 7.2.4. Global Stem Cell Therapy by: Application (Value)
        • 7.2.4.1. Musculoskeletal Disorders
        • 7.2.4.2. Cardiovascular Diseases
        • 7.2.4.3. Neurological Disorders
        • 7.2.4.4. Oncology
        • 7.2.4.5. Wounds and Injuries
        • 7.2.4.6. Others
      • 7.2.5. Global Stem Cell Therapy by: End User (Value)
        • 7.2.5.1. Hospitals & Clinics
        • 7.2.5.2. Academic & Research Institutes
        • 7.2.5.3. Biotechnology & Pharmaceutical Companies
      • 7.2.6. Global Stem Cell Therapy Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Stem Cell Therapy: by Application(USD Million)
  • Table 2. Stem Cell Therapy Musculoskeletal Disorders , by Region USD Million (2019-2024)
  • Table 3. Stem Cell Therapy Cardiovascular Diseases , by Region USD Million (2019-2024)
  • Table 4. Stem Cell Therapy Neurological Disorders , by Region USD Million (2019-2024)
  • Table 5. Stem Cell Therapy Oncology , by Region USD Million (2019-2024)
  • Table 6. Stem Cell Therapy Wounds and Injuries , by Region USD Million (2019-2024)
  • Table 7. Stem Cell Therapy Others , by Region USD Million (2019-2024)
  • Table 8. Stem Cell Therapy: by Therapy Type(USD Million)
  • Table 9. Stem Cell Therapy Autologous Stem Cell Therapy , by Region USD Million (2019-2024)
  • Table 10. Stem Cell Therapy Allogeneic Stem Cell Therapy , by Region USD Million (2019-2024)
  • Table 11. Stem Cell Therapy: by Cell Source(USD Million)
  • Table 12. Stem Cell Therapy Adult Stem Cells , by Region USD Million (2019-2024)
  • Table 13. Stem Cell Therapy Embryonic Stem Cells , by Region USD Million (2019-2024)
  • Table 14. Stem Cell Therapy Induced Pluripotent Stem Cells (iPSCs) , by Region USD Million (2019-2024)
  • Table 15. Stem Cell Therapy: by Application(USD Million)
  • Table 16. Stem Cell Therapy Musculoskeletal Disorders , by Region USD Million (2019-2024)
  • Table 17. Stem Cell Therapy Cardiovascular Diseases , by Region USD Million (2019-2024)
  • Table 18. Stem Cell Therapy Neurological Disorders , by Region USD Million (2019-2024)
  • Table 19. Stem Cell Therapy Oncology , by Region USD Million (2019-2024)
  • Table 20. Stem Cell Therapy Wounds and Injuries , by Region USD Million (2019-2024)
  • Table 21. Stem Cell Therapy Others , by Region USD Million (2019-2024)
  • Table 22. Stem Cell Therapy: by End User(USD Million)
  • Table 23. Stem Cell Therapy Hospitals & Clinics , by Region USD Million (2019-2024)
  • Table 24. Stem Cell Therapy Academic & Research Institutes , by Region USD Million (2019-2024)
  • Table 25. Stem Cell Therapy Biotechnology & Pharmaceutical Companies , by Region USD Million (2019-2024)
  • Table 26. South America Stem Cell Therapy, by Country USD Million (2019-2024)
  • Table 27. South America Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 28. South America Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 29. South America Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 30. South America Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 31. Brazil Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 32. Brazil Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 33. Brazil Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 34. Brazil Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 35. Argentina Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 36. Argentina Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 37. Argentina Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 38. Argentina Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 39. Rest of South America Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 40. Rest of South America Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 41. Rest of South America Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 42. Rest of South America Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 43. Asia Pacific Stem Cell Therapy, by Country USD Million (2019-2024)
  • Table 44. Asia Pacific Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 45. Asia Pacific Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 46. Asia Pacific Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 47. Asia Pacific Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 48. China Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 49. China Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 50. China Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 51. China Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 52. Japan Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 53. Japan Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 54. Japan Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 55. Japan Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 56. India Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 57. India Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 58. India Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 59. India Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 60. South Korea Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 61. South Korea Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 62. South Korea Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 63. South Korea Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 64. Taiwan Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 65. Taiwan Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 66. Taiwan Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 67. Taiwan Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 68. Australia Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 69. Australia Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 70. Australia Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 71. Australia Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 72. Rest of Asia-Pacific Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 73. Rest of Asia-Pacific Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 74. Rest of Asia-Pacific Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 75. Rest of Asia-Pacific Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 76. Europe Stem Cell Therapy, by Country USD Million (2019-2024)
  • Table 77. Europe Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 78. Europe Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 79. Europe Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 80. Europe Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 81. Germany Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 82. Germany Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 83. Germany Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 84. Germany Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 85. France Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 86. France Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 87. France Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 88. France Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 89. Italy Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 90. Italy Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 91. Italy Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 92. Italy Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 93. United Kingdom Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 94. United Kingdom Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 95. United Kingdom Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 96. United Kingdom Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 97. Netherlands Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 98. Netherlands Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 99. Netherlands Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 100. Netherlands Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 101. Rest of Europe Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 102. Rest of Europe Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 103. Rest of Europe Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 104. Rest of Europe Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 105. MEA Stem Cell Therapy, by Country USD Million (2019-2024)
  • Table 106. MEA Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 107. MEA Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 108. MEA Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 109. MEA Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 110. Middle East Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 111. Middle East Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 112. Middle East Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 113. Middle East Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 114. Africa Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 115. Africa Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 116. Africa Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 117. Africa Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 118. North America Stem Cell Therapy, by Country USD Million (2019-2024)
  • Table 119. North America Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 120. North America Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 121. North America Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 122. North America Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 123. United States Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 124. United States Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 125. United States Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 126. United States Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 127. Canada Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 128. Canada Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 129. Canada Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 130. Canada Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 131. Mexico Stem Cell Therapy, by Therapy Type USD Million (2019-2024)
  • Table 132. Mexico Stem Cell Therapy, by Cell Source USD Million (2019-2024)
  • Table 133. Mexico Stem Cell Therapy, by Application USD Million (2019-2024)
  • Table 134. Mexico Stem Cell Therapy, by End User USD Million (2019-2024)
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Company Basic Information, Sales Area and Its Competitors
  • Table 146. Company Basic Information, Sales Area and Its Competitors
  • Table 147. Company Basic Information, Sales Area and Its Competitors
  • Table 148. Company Basic Information, Sales Area and Its Competitors
  • Table 149. Company Basic Information, Sales Area and Its Competitors
  • Table 150. Stem Cell Therapy: by Application(USD Million)
  • Table 151. Stem Cell Therapy Musculoskeletal Disorders , by Region USD Million (2027-2032)
  • Table 152. Stem Cell Therapy Cardiovascular Diseases , by Region USD Million (2027-2032)
  • Table 153. Stem Cell Therapy Neurological Disorders , by Region USD Million (2027-2032)
  • Table 154. Stem Cell Therapy Oncology , by Region USD Million (2027-2032)
  • Table 155. Stem Cell Therapy Wounds and Injuries , by Region USD Million (2027-2032)
  • Table 156. Stem Cell Therapy Others , by Region USD Million (2027-2032)
  • Table 157. Stem Cell Therapy: by Therapy Type(USD Million)
  • Table 158. Stem Cell Therapy Autologous Stem Cell Therapy , by Region USD Million (2027-2032)
  • Table 159. Stem Cell Therapy Allogeneic Stem Cell Therapy , by Region USD Million (2027-2032)
  • Table 160. Stem Cell Therapy: by Cell Source(USD Million)
  • Table 161. Stem Cell Therapy Adult Stem Cells , by Region USD Million (2027-2032)
  • Table 162. Stem Cell Therapy Embryonic Stem Cells , by Region USD Million (2027-2032)
  • Table 163. Stem Cell Therapy Induced Pluripotent Stem Cells (iPSCs) , by Region USD Million (2027-2032)
  • Table 164. Stem Cell Therapy: by Application(USD Million)
  • Table 165. Stem Cell Therapy Musculoskeletal Disorders , by Region USD Million (2027-2032)
  • Table 166. Stem Cell Therapy Cardiovascular Diseases , by Region USD Million (2027-2032)
  • Table 167. Stem Cell Therapy Neurological Disorders , by Region USD Million (2027-2032)
  • Table 168. Stem Cell Therapy Oncology , by Region USD Million (2027-2032)
  • Table 169. Stem Cell Therapy Wounds and Injuries , by Region USD Million (2027-2032)
  • Table 170. Stem Cell Therapy Others , by Region USD Million (2027-2032)
  • Table 171. Stem Cell Therapy: by End User(USD Million)
  • Table 172. Stem Cell Therapy Hospitals & Clinics , by Region USD Million (2027-2032)
  • Table 173. Stem Cell Therapy Academic & Research Institutes , by Region USD Million (2027-2032)
  • Table 174. Stem Cell Therapy Biotechnology & Pharmaceutical Companies , by Region USD Million (2027-2032)
  • Table 175. South America Stem Cell Therapy, by Country USD Million (2027-2032)
  • Table 176. South America Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 177. South America Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 178. South America Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 179. South America Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 180. Brazil Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 181. Brazil Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 182. Brazil Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 183. Brazil Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 184. Argentina Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 185. Argentina Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 186. Argentina Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 187. Argentina Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 188. Rest of South America Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 189. Rest of South America Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 190. Rest of South America Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 191. Rest of South America Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 192. Asia Pacific Stem Cell Therapy, by Country USD Million (2027-2032)
  • Table 193. Asia Pacific Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 194. Asia Pacific Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 195. Asia Pacific Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 196. Asia Pacific Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 197. China Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 198. China Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 199. China Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 200. China Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 201. Japan Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 202. Japan Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 203. Japan Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 204. Japan Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 205. India Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 206. India Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 207. India Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 208. India Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 209. South Korea Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 210. South Korea Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 211. South Korea Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 212. South Korea Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 213. Taiwan Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 214. Taiwan Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 215. Taiwan Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 216. Taiwan Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 217. Australia Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 218. Australia Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 219. Australia Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 220. Australia Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 221. Rest of Asia-Pacific Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 222. Rest of Asia-Pacific Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 223. Rest of Asia-Pacific Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 224. Rest of Asia-Pacific Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 225. Europe Stem Cell Therapy, by Country USD Million (2027-2032)
  • Table 226. Europe Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 227. Europe Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 228. Europe Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 229. Europe Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 230. Germany Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 231. Germany Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 232. Germany Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 233. Germany Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 234. France Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 235. France Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 236. France Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 237. France Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 238. Italy Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 239. Italy Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 240. Italy Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 241. Italy Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 242. United Kingdom Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 243. United Kingdom Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 244. United Kingdom Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 245. United Kingdom Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 246. Netherlands Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 247. Netherlands Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 248. Netherlands Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 249. Netherlands Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 250. Rest of Europe Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 251. Rest of Europe Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 252. Rest of Europe Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 253. Rest of Europe Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 254. MEA Stem Cell Therapy, by Country USD Million (2027-2032)
  • Table 255. MEA Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 256. MEA Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 257. MEA Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 258. MEA Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 259. Middle East Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 260. Middle East Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 261. Middle East Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 262. Middle East Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 263. Africa Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 264. Africa Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 265. Africa Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 266. Africa Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 267. North America Stem Cell Therapy, by Country USD Million (2027-2032)
  • Table 268. North America Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 269. North America Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 270. North America Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 271. North America Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 272. United States Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 273. United States Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 274. United States Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 275. United States Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 276. Canada Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 277. Canada Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 278. Canada Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 279. Canada Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 280. Mexico Stem Cell Therapy, by Therapy Type USD Million (2027-2032)
  • Table 281. Mexico Stem Cell Therapy, by Cell Source USD Million (2027-2032)
  • Table 282. Mexico Stem Cell Therapy, by Application USD Million (2027-2032)
  • Table 283. Mexico Stem Cell Therapy, by End User USD Million (2027-2032)
  • Table 284. Research Programs/Design for This Report
  • Table 285. Key Data Information from Secondary Sources
  • Table 286. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Stem Cell Therapy: by Application USD Million (2019-2024)
  • Figure 5. Global Stem Cell Therapy: by Therapy Type USD Million (2019-2024)
  • Figure 6. Global Stem Cell Therapy: by Cell Source USD Million (2019-2024)
  • Figure 7. Global Stem Cell Therapy: by Application USD Million (2019-2024)
  • Figure 8. Global Stem Cell Therapy: by End User USD Million (2019-2024)
  • Figure 9. South America Stem Cell Therapy Share (%), by Country
  • Figure 10. Asia Pacific Stem Cell Therapy Share (%), by Country
  • Figure 11. Europe Stem Cell Therapy Share (%), by Country
  • Figure 12. MEA Stem Cell Therapy Share (%), by Country
  • Figure 13. North America Stem Cell Therapy Share (%), by Country
  • Figure 14. Global Stem Cell Therapy share by Players 2024 (%)
  • Figure 15. Global Stem Cell Therapy share by Players (Top 3) 2024(%)
  • Figure 16. Global Stem Cell Therapy share by Players (Top 5) 2024(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Mesoblast Ltd. Revenue, Net Income and Gross profit
  • Figure 19. Mesoblast Ltd. Revenue: by Geography 2024
  • Figure 20. Athersys, Inc. Revenue, Net Income and Gross profit
  • Figure 21. Athersys, Inc. Revenue: by Geography 2024
  • Figure 22. Osiris Therapeutics, Inc. Revenue, Net Income and Gross profit
  • Figure 23. Osiris Therapeutics, Inc. Revenue: by Geography 2024
  • Figure 24. Takeda Pharmaceutical Company Limited Revenue, Net Income and Gross profit
  • Figure 25. Takeda Pharmaceutical Company Limited Revenue: by Geography 2024
  • Figure 26. Vericel Corporation Revenue, Net Income and Gross profit
  • Figure 27. Vericel Corporation Revenue: by Geography 2024
  • Figure 28. Pluristem Therapeutics Inc. Revenue, Net Income and Gross profit
  • Figure 29. Pluristem Therapeutics Inc. Revenue: by Geography 2024
  • Figure 30. BioTime, Inc. (Lineage Cell Therapeutics) Revenue, Net Income and Gross profit
  • Figure 31. BioTime, Inc. (Lineage Cell Therapeutics) Revenue: by Geography 2024
  • Figure 32. Cynata Therapeutics Limited Revenue, Net Income and Gross profit
  • Figure 33. Cynata Therapeutics Limited Revenue: by Geography 2024
  • Figure 34. Thermo Fisher Scientific Inc. Revenue, Net Income and Gross profit
  • Figure 35. Thermo Fisher Scientific Inc. Revenue: by Geography 2024
  • Figure 36. STEMCELL Technologies Inc. Revenue, Net Income and Gross profit
  • Figure 37. STEMCELL Technologies Inc. Revenue: by Geography 2024
  • Figure 38. FUJIFILM Cellular Dynamics, Inc. Revenue, Net Income and Gross profit
  • Figure 39. FUJIFILM Cellular Dynamics, Inc. Revenue: by Geography 2024
  • Figure 40. BrainStorm Cell Therapeutics Inc. Revenue, Net Income and Gross profit
  • Figure 41. BrainStorm Cell Therapeutics Inc. Revenue: by Geography 2024
  • Figure 42. Gamida Cell Ltd. Revenue, Net Income and Gross profit
  • Figure 43. Gamida Cell Ltd. Revenue: by Geography 2024
  • Figure 44. BlueRock Therapeutics Revenue, Net Income and Gross profit
  • Figure 45. BlueRock Therapeutics Revenue: by Geography 2024
  • Figure 46. ReNeuron Group plc Revenue, Net Income and Gross profit
  • Figure 47. ReNeuron Group plc Revenue: by Geography 2024
  • Figure 48. Global Stem Cell Therapy: by Application USD Million (2027-2032)
  • Figure 49. Global Stem Cell Therapy: by Therapy Type USD Million (2027-2032)
  • Figure 50. Global Stem Cell Therapy: by Cell Source USD Million (2027-2032)
  • Figure 51. Global Stem Cell Therapy: by Application USD Million (2027-2032)
  • Figure 52. Global Stem Cell Therapy: by End User USD Million (2027-2032)
  • Figure 53. South America Stem Cell Therapy Share (%), by Country
  • Figure 54. Asia Pacific Stem Cell Therapy Share (%), by Country
  • Figure 55. Europe Stem Cell Therapy Share (%), by Country
  • Figure 56. MEA Stem Cell Therapy Share (%), by Country
  • Figure 57. North America Stem Cell Therapy Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Mesoblast Ltd.
  • Athersys, Inc.
  • Osiris Therapeutics, Inc.
  • Takeda Pharmaceutical Company Limited
  • Vericel Corporation
  • Pluristem Therapeutics Inc.
  • BioTime, Inc. (Lineage Cell Therapeutics)
  • Cynata Therapeutics Limited
  • Thermo Fisher Scientific Inc.
  • STEMCELL Technologies Inc.
  • FUJIFILM Cellular Dynamics, Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Gamida Cell Ltd.
  • BlueRock Therapeutics
  • ReNeuron Group plc
Select User Access Type

Key Highlights of Report


May 2021 229 Pages 76 Tables Base Year: 2024 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Stem Cell Therapy Market Quantitative research analysis
Global Stem Cell Therapy Market Qualitative Industry Analysis
Global Stem Cell Therapy Market Quantitative research analysis
Global Stem Cell Therapy Market Qualitative Industry Analysis
Global Stem Cell Therapy Market Quantitative research analysis
Global Stem Cell Therapy Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Stem Cell Therapy market are Mesoblast Ltd., Athersys, Inc., Osiris Therapeutics, Inc., Takeda Pharmaceutical Company Limited, Vericel Corporation, Pluristem Therapeutics Inc., BioTime, Inc. (Lineage Cell Therapeutics), Cynata Therapeutics Limited, Thermo Fisher Scientific Inc., STEMCELL Technologies Inc., FUJIFILM Cellular Dynamics, Inc., BrainStorm Cell Therapeutics Inc., Gamida Cell Ltd., BlueRock Therapeutics and ReNeuron Group plc, to name a few.
"Growing popularity of stem cell banking for future therapeutic use. " is seen as one of major influencing trends for Stem Cell Therapy Market during projected period 2024-2032.

Know More About Global Stem Cell Therapy Market Report?

Have a Query? Click Here

Other Related Reports

Diabetic Retinopathy Comprehensive Study by Type (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs, Vitrectomy), Application (Hospitals, Clinics and laboratories, Others), Retinopathy (Pr...
$ 3650
Organ Transplantation Comprehensive Study by Type (Preservation Solutions, Transplant Diagnostics, Tissue Products, Others (Immunosuppressive drugs)), Application (Children, Adults, Senior Citizens),...
$ 3750
Nocturia Comprehensive Study by Type (Nocturnal Polyuria, Bladder Storage Problems, Mixed Nocturia), Application (Hospitals, Clinics), Drug Form (Tablets, Nasal Spray), Types (Polyuria, Nocturnal Pol...
$ 3650
Shoulder Labrum Repair Comprehensive Study by Type (PLA Resorbable Suture Anchor, Biocomposite Suture Anchor, PEEK Suture Anchor, Metal Suture Anchor, All-Suture Anchor), Application (Rotator Cuff Te...
$ 3650
Breast Biopsy Comprehensive Study by Type (Core Needle Biopsy (CNB), Vacuum-Assisted Biopsy (VAB), Fine Needle Aspiration Biopsy (FNAB)), Application (Hospitals, Clinics, Diagnostic Centers, Others),...
$ 3750
Asthma Medication Comprehensive Study by Type (Quick-Relief Medications, Long-Term Control Medications, Asthma Medications During Pregnancy), Application (Children, Adolescent, Adult), Therapy (Relie...
$ 3750
Diabetic Retinopathy Comprehensive Study by Type (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs, Vitrectomy), Application (Hospitals, Clinics and laboratories, Others), Retinopathy (Pr...
$ 3650
Organ Transplantation Comprehensive Study by Type (Preservation Solutions, Transplant Diagnostics, Tissue Products, Others (Immunosuppressive drugs)), Application (Children, Adults, Senior Citizens),...
$ 3750
Nocturia Comprehensive Study by Type (Nocturnal Polyuria, Bladder Storage Problems, Mixed Nocturia), Application (Hospitals, Clinics), Drug Form (Tablets, Nasal Spray), Types (Polyuria, Nocturnal Pol...
$ 3650
Shoulder Labrum Repair Comprehensive Study by Type (PLA Resorbable Suture Anchor, Biocomposite Suture Anchor, PEEK Suture Anchor, Metal Suture Anchor, All-Suture Anchor), Application (Rotator Cuff Te...
$ 3650
Breast Biopsy Comprehensive Study by Type (Core Needle Biopsy (CNB), Vacuum-Assisted Biopsy (VAB), Fine Needle Aspiration Biopsy (FNAB)), Application (Hospitals, Clinics, Diagnostic Centers, Others),...
$ 3750
Asthma Medication Comprehensive Study by Type (Quick-Relief Medications, Long-Term Control Medications, Asthma Medications During Pregnancy), Application (Children, Adolescent, Adult), Therapy (Relie...
$ 3750
Diabetic Retinopathy Comprehensive Study by Type (Laser surgery, Injection of corticosteroids, Anti-VEGF drugs, Vitrectomy), Application (Hospitals, Clinics and laboratories, Others), Retinopathy (Pr...
$ 3650
Organ Transplantation Comprehensive Study by Type (Preservation Solutions, Transplant Diagnostics, Tissue Products, Others (Immunosuppressive drugs)), Application (Children, Adults, Senior Citizens),...
$ 3750
Nocturia Comprehensive Study by Type (Nocturnal Polyuria, Bladder Storage Problems, Mixed Nocturia), Application (Hospitals, Clinics), Drug Form (Tablets, Nasal Spray), Types (Polyuria, Nocturnal Pol...
$ 3650
Shoulder Labrum Repair Comprehensive Study by Type (PLA Resorbable Suture Anchor, Biocomposite Suture Anchor, PEEK Suture Anchor, Metal Suture Anchor, All-Suture Anchor), Application (Rotator Cuff Te...
$ 3650